Multimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Authors
Carr, THAdelman, C
Barnicle, A
Kozarewa, I
Luke, S
Lai, Z
Menon, S
Hollis, S
Dougherty, B
Harrington, EA
Barrett, JC
Goessl, C
Saad, F
Sala, N
Clarke, Noel W
Hodgson, D
Affiliation
AstraZeneca, Cambridge, UKIssue Date
2018
Metadata
Show full item recordCitation
Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, et al. 97P Multimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC). Annals of Oncology. 2018;29(suppl_8).Journal
Annals of OncologyDOI
10.1093/annonc/mdy269.095PubMed ID
No PMIDAdditional Links
https://dx.doi.org/10.1093/annonc/mdy269.095Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy269.095